Analysts Offer Insights on Healthcare Companies: Celldex (CLDX) and Recursion Pharmaceuticals (RXRX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Celldex (CLDX – Research Report) and Recursion Pharmaceuticals (RXRX – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Celldex (CLDX)
LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Celldex today and set a price target of $61.00. The company’s shares closed last Wednesday at $30.84.
According to TipRanks.com, Slutsky is a top 100 analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Celldex with a $47.40 average price target, implying an 85.5% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $42.00 price target.
See today’s best-performing stocks on TipRanks >>
Recursion Pharmaceuticals (RXRX)
In a report released today, Gil Blum from Needham maintained a Buy rating on Recursion Pharmaceuticals, with a price target of $8.00. The company’s shares closed last Wednesday at $3.78.
According to TipRanks.com, Blum is a 4-star analyst with an average return of
Recursion Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $7.75.
